ArticleClinical and experimental medicine2025
Urinary 8-oxoGuo as a potential novel evaluation biomarker for patients with systemic lupus erythematosus.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveWe evaluated the urinary levels of 8-oxo-7,8-dihydroguanosine/creatinine(8-oxoGuo/Cr) and 8-oxo-7,8-dihydroguanosine/specific gravity (8-oxoGuo/SG) as potential biomarkers for diagnosing systemic lupus erythematosus and determining disease activity.
methodsA total of 160 participants, including 86 patients meeting American College (ACR) criteria for systemic lupus erythematosus (SLE) and 74 control individuals matched for age and gender, were enrolled in the study. Urine RNA oxidation marker 8-oxo-7,8-dihydroguanosine (8-oxoGuo) detected by HPLC-electrochemical and normalized to urine creatinine and specific gravity. SLE disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2000), a widely utilized and scientifically validated clinical assessment tool to measure disease activity in SLE patientsResults: There were significant differences between SLE patients and health controls in terms of serum ALT (P = 0.013), serum TP (P < 0.001), serum ALB (P < 0. 001), TBIL (P < 0. 001), DBIL (P < 0. 001), GLU (P < 0. 001), UREA (P = 0.017), Scr (P = 0.025), and UREA/Scr (P < 0. 001). Important disease indicators of SLE patients were showed in Table 2. Urine concentrations of 8-oxoGuo/Cr and 8-oxoGuo/SG were significantly higher in patients with SLE. In SLE patients, the values of 8-oxoG/Cr were higher at 2.32 ± 1.07 μmol/mol compared to healthy controls at 1.62 ± 0.65 μmol/mol, and the values of 8-oxoG/SG were higher at 2.06(1.63,2.73) pg/μL compared to healthy controls at 1.32(0.68,2.01)pg/μL. The AUCs for 8-oxoGuo/Cr and 8-oxoGuo/SG were both higher than 0.7, they were 0.733 (P < 0.0001) and 0.767 (P < 0.0001), respectively. The 95% confidence interval (CI) for the AUC of 8-oxoGuo/Cr and 8-oxoGuo/SG were 0.656-0.811 and 0.691-0.843, respectively. Higher 8-oxoG/Cr levels in SLE patients were associated with ESR (Spearman's rho = 0.242, P = 0.003) and SLEDAI-2000 score (Spearman's rho = 0.328, P < 0.001). Higher 8-oxoG/SG levels in SLE patients were negative associated with 24H UA (Spearman's rho = - 0.292, P < 0.001) and positive associated with SLEDAI-2000 score (Spearman's rho = 0.195, P < 0.016). Additionally, the levels of 8-oxoGuo/Cr and 8-oxoGuo/SG were significantly higher in disease activity groups of patients with SLE compared to both the control group and patients in remission.
conclusionsUrine 8-oxoGuo/Cr and 8-oxoGuo/SG could be a potential biomarker associated with severity and disease activity in individuals diagnosed with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.